Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery (NCT01344226), a registered phase not stated study. The primary outcome is Investigate Clinical Outcomes for Intraocular Pressure After Treatment With Lotemax (Loteprednol Ophthalmic Solution) 0.5% QID in Subjects Who Have Undergone Cataract Extraction With Posterior Chamber Intraocular Implantation..

2. Clinical Question

The study’s brief summary focuses on intraocular pressure in patients treated with Lotemax after surgery. The primary outcome description specifies change from baseline during the first 6 weeks following cataract surgery. The endpoint is framed as a clinical outcome among treated participants, rather than as a stated treatment contrast against a comparable control group.

The registry record identifies the study as completed and reports enrollment of 49. It does not report the observed mean pressure change, its standard error, or an inferential comparison. Thus, the record defines the question but does not provide the outcome estimate needed to assess the observed pattern or its precision.

3. Trial Design

This completed clinical study examined loteprednol ophthalmic solution 0.5% after cataract extraction with posterior chamber intraocular implantation. The intervention is listed as a drug, and the study title specifies QID use. The reported enrollment is 49. The registry lists Toyos Clinic as sponsor, with a start date of April 2011 and primary completion in September 2013.

The record does not describe a randomized comparison. It states that allocation was not stated and that arms are not a like-for-like control comparison. Accordingly, the design should not be read as establishing a randomized treatment contrast. The adverse-event record gives one group receiving loteprednol, with 49 at risk for both serious and other adverse events. Further details about group assignment or any additional group structure are not reported in the registry record.

The primary outcome is intraocular pressure change from baseline to 6 weeks, expressed in mm Hg. The record lists the outcome parameter as a mean and its dispersion as a standard error. It also names secondary outcomes concerning ETDRS letters read over the early postoperative period, cell scores at 6 weeks post phacoemulsification, and flare scores in the early postoperative period.

Although the registry marks the study completed, it lists no analyses and does not report numerical results for the primary or named secondary outcomes. The sample-size justification, protocol details, analysis populations, and statistical analysis plan are not reported in the registry record. These omissions limit the ability to reconstruct how the study was intended to be analyzed or to compare its stated aims with completed analyses.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: patients had to be off of steroids for 14 days with no depot steroid injection for 30 days

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Investigate Clinical Outcomes for Intraocular Pressure After Treatment With Lotemax (Loteprednol Ophthalmic Solution) 0.5% QID in Subjects Who Have Undergone Cataract Extraction With Posterior Chamber Intraocular Implantation., measured over baseline to 6 weeks.

The primary endpoint is the change in intraocular pressure from baseline to 6 weeks after cataract surgery among participants treated with loteprednol ophthalmic solution 0.5% QID. Pressure is measured in mm Hg, and the listed summary is a mean with standard error as the measure of dispersion.

In general, intraocular pressure is a continuous measurement, so a mean change describes the average direction and magnitude of change across the analyzed participants. The endpoint’s baseline-to-follow-up framing focuses on change over the postoperative period rather than pressure at a single time point alone. Such a measure can describe the observed course in the treated group, but without a comparable control group it does not by itself isolate the contribution of treatment from other influences, including the passage of time and the postoperative course.

The standard error describes the precision of the estimated mean, not the spread of individual participants’ measurements. The registry record does not report the mean change, standard error, participant count for the endpoint analysis, or a confidence interval. It therefore specifies what was intended to be measured but does not provide the numerical endpoint result or its precision.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The record identifies a continuous primary endpoint summarized as a mean, with standard error as the dispersion measure. It does not report a statistical analysis or a numerical result. The explanations below are general descriptions of these methods and their interpretation; they do not imply that a particular procedure was used in this study unless the registry record states it.

What does a mean change represent?

For a continuous outcome measured at baseline and follow-up, a change score represents the follow-up value relative to the baseline value for each participant. A mean change then summarizes the average of those individual changes in the analysis group. In this study, the outcome is defined as intraocular pressure change in mm Hg from baseline to 6 weeks. The registry record does not specify the exact calculation procedure, the endpoint analysis population, or how participants without measurements at both time points were handled.

A group mean can be useful for describing the average pattern, but it does not show the full distribution of individual responses. Participants can have different changes even when the group average is near a particular value. The mean also does not establish why the change occurred. In an uncontrolled before-and-after setting, changes may reflect multiple influences, not solely the intervention.

How is standard error different from variability?

In general, the standard error quantifies the sampling uncertainty of an estimated mean. It is not the same as a standard deviation, which describes variability among individual observations. A smaller standard error indicates a more precisely estimated mean under the assumptions of the analysis; it does not necessarily mean that individual measurements are similar to one another. The registry record names standard error as the dispersion measure but reports no value, so the precision of the endpoint estimate cannot be assessed.

A confidence interval is a range of values compatible with the data under a statistical model and a specified confidence procedure. In general, it communicates uncertainty around an estimate more directly than a point estimate alone. No confidence interval is reported for the primary endpoint in the registry record. A p-value, if reported, would address compatibility with a specified null hypothesis under the analysis assumptions; no p-value or analysis result is listed.

Why does the comparison structure matter?

In general, a comparison group can help distinguish changes associated with an intervention from changes that would also occur without it. Random allocation, when used and properly implemented, can support a more credible comparison by reducing systematic differences between groups. The registry record does not state allocation and specifically cautions that the arms are not a like-for-like control comparison. The available information therefore does not establish a randomized controlled design or a comparable untreated group.

A pre-to-post mean change in a treated group can still describe what happened among those with measurements, but it should not automatically be called a treatment effect. Time, surgery, participant characteristics, measurement conditions, and other factors may influence change. These are general interpretive considerations; the record does not describe which factors were measured or adjusted for.

What can planning calculations tell readers?

In general, a sample-size calculation estimates how many participants would be needed to detect a specified effect under assumptions about the outcome, variability, significance level, allocation, and statistical model. It is a planning exercise, not a result of the trial and not a measure of the probability that a completed study has found a true effect. Calculations based on an observed effect are especially dependent on that estimate and should be treated as illustrations rather than as the study’s original design rationale.

The planning assumptions described for this study use a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the effect to detect is a stated fraction of the observed effect. Those assumptions describe an illustration, not a documented protocol justification. The record does not report the original sample-size justification. Any such planning figures are not observed power, and they cannot replace the missing endpoint estimate or its uncertainty.

What does the absence of analyses mean?

The registry record lists zero analyses and supplies no numerical outcome results. This should be interpreted as an absence of reported analyses in the registry record, not as evidence that analyses found no effect or no change. The record also does not report whether analyses were conducted elsewhere, how missing observations were handled, whether estimates were adjusted, or whether model assumptions were checked. Those details cannot be inferred from the outcome definitions alone.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("Patients Receiving Loteprednol 0.5% Qid Post Phaco")
n   <- c(49)
m   <- c(-1.8)
sp  <- c(1.06)
sd  <- sp * sqrt(n)      # standard errors converted to SDs
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  Patients Receiving Loteprednol 0.5% Qid Post Phaco  49  -1.800  7.420  -3.931  0.331

11. Multiplicity, Missing Data and Analysis Populations

The record lists a primary outcome and names secondary outcomes involving ETDRS letters read, cell scores, and flare scores. It also reports four outcome measures in total, while the named secondary outcomes account for three listed measures. The additional outcome measure is not identified in the registry record. No outcome analyses or results are reported.

Multiplicity arises in general when multiple outcomes, time points, groups, or statistical tests are examined. Without a prespecified approach, repeated testing can increase the chance of finding an apparently notable result by chance. The registry record does not report whether any multiplicity adjustment was planned or used, how the primary outcome was prioritized in analysis, or whether the secondary outcomes were treated as confirmatory or exploratory. No multiplicity procedure should be assumed.

The record also does not report missing-data counts, reasons for missingness, imputation methods, or sensitivity analyses. It does not state which participants were included in the primary analysis or define an analysis population. Enrollment of 49 does not establish that all enrolled participants contributed data at each endpoint. The number analyzed for intraocular pressure and the handling of participants without complete measurements are not reported in the registry record.

These omissions matter because missingness and analysis choices can affect both the estimate and its uncertainty. General statistical methods can address some forms of incomplete data, but their suitability depends on why data are missing and on the assumptions used. No particular missing-data method or analysis population can be attributed to this study based on the registry record.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent non-serious adverse event terms

The registry lists 49 participants at risk for serious adverse events and 0 affected. For other adverse events, it lists 49 at risk and 3 affected. No serious adverse-event terms are listed. These are the safety figures recorded for the group receiving loteprednol 0.5% QID after phacoemulsification.

In general, an at-risk count identifies the group denominator used for a safety category, while an affected count identifies the number recorded as having an event in that category. The registry record does not provide event descriptions for the other adverse events, so their nature and severity cannot be characterized from this entry. It also does not provide further detail about event collection, follow-up completeness, or whether participants could have experienced more than one event.

The deaths field is not reported in the registry record; it should not be interpreted as a reported zero. The serious-event count is recorded as 0, but that figure does not establish that no safety concerns of any kind occurred. The separate other-adverse-event count is 3. With no comparable control group described, these counts do not establish whether the recorded events were more or less frequent than they would have been under another treatment or no treatment.

13. What the Result Does, and Does Not, Mean

The registry record gives a defined clinical question: it describes assessment of mean intraocular pressure change from baseline to 6 weeks in participants treated with loteprednol ophthalmic solution 0.5% QID after cataract surgery. It reports enrollment of 49 and marks the study completed. It also identifies several postoperative secondary outcomes and includes limited adverse-event counts.

What the record does not give is the primary outcome estimate or its precision. There is no reported mean change in mm Hg, standard error, confidence interval, or statistical analysis. No secondary outcome results are listed either. Therefore, readers cannot determine from this record the direction or size of the observed pressure change, how uncertain an estimate might be, or whether the recorded outcomes differed across any groups.

The design description does not support a controlled causal comparison: allocation was not stated, and the record cautions that arms are not a like-for-like control comparison. A change observed within a treated group, even if it were reported, would describe change over time and would not by itself show what would have happened without treatment. That distinction is general to uncontrolled comparisons and is especially important when interpreting before-and-after measurements.

The safety record lists 0 serious adverse events among 49 at risk and 3 affected for other adverse events among 49 at risk. The deaths value is not reported in the registry record, and no serious-event terms are listed. These entries should be read as registry safety counts, not as a complete description of event types or as a comparative safety estimate.

In short, the record documents the study’s focus, status, enrollment, outcome definitions, and some safety counts. It does not provide enough outcome information to characterize the primary result or draw a treatment-effect conclusion. Missing results are not equivalent to evidence of no change, and the absence of reported analyses is not an analysis finding.

14. Why This Trial Matters Statistically

This study raises statistical issues that are common in clinical research: how to interpret change from baseline, how to distinguish a descriptive result from a treatment contrast, and how much can be learned when outcome estimates and uncertainty measures are not posted. The primary endpoint is a continuous measure summarized as a mean, making the distinction between the estimated average change and the variability of individual measurements important.

The registry record also makes the comparison structure relevant to interpretation. It does not state allocation and warns that the arms are not a like-for-like control comparison. In general, a before-and-after result can describe the course of a measurement in a treated group, but it cannot by itself separate treatment-associated change from other changes over time. Clear reporting of the design and analysis is therefore essential to avoid overstating what an estimate means.

Another statistical issue is precision. Naming standard error as the dispersion measure signals that uncertainty around the mean was intended to be characterized, but the record does not post the estimate or its standard error. Without those values, readers cannot evaluate the size or precision of the primary result. The absence of analyses and missing-data information further limits assessment of how participants contributed to the endpoint.

Finally, the record illustrates why planning calculations and trial results must be kept distinct. A planning illustration based on an observed effect is not the original sample-size justification and is not observed power. The original justification is not reported in the registry record. These distinctions help readers separate study design assumptions, descriptive summaries, and inferential conclusions.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record gives limited detail about the study design beyond its completed status, enrollment, intervention, and outcome descriptions. It does not state allocation, and it cautions that arms are not a like-for-like control comparison. Further information about any comparator, group assignment, eligibility criteria, masking, or treatment administration is not reported in the registry record.

The central limitation for interpreting outcomes is the absence of posted numerical results. There is no mean intraocular pressure change, standard error, confidence interval, or analysis result. Results for the named secondary outcomes are also not reported. Although the record lists four outcome measures, it names only three secondary outcomes in addition to the primary endpoint; the other measure is not identified.

The record does not describe the primary analysis population, endpoint-specific participant counts, missing-data handling, or statistical model. It does not report an analysis plan, sample-size justification, or any multiplicity procedure. These omissions prevent assessment of whether the analyses followed a prespecified plan, how incomplete measurements were handled, or how uncertainty was estimated in practice.

The safety entry is also limited: it lists affected counts but provides no terms for serious events and no description of the other adverse events. The deaths value is not reported in the registry record. There is no comparable control group identified for interpreting these counts. Taken together, the registry record supports description of the study’s stated aims and recorded safety counts, but not a detailed assessment of efficacy, precision, or comparative safety.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery — NCT01344226.
• Registry record last updated 2018-10-22; status last verified 2018-01.
• Results first posted 2018-10-22.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

This completed study, sponsored by Toyos Clinic, enrolled 49 participants and evaluated loteprednol ophthalmic solution 0.5% QID after cataract surgery. The primary outcome was mean intraocular pressure change from baseline to 6 weeks, measured in mm Hg, with standard error specified as the dispersion measure. The record names secondary outcomes concerning ETDRS letters read, cell scores, and flare scores.

Allocation was not stated, and the registry cautions that the arms are not a like-for-like control comparison. No analyses or numerical outcome results are reported. The safety entry lists 0 serious adverse events among 49 at risk and 3 affected for other adverse events among 49 at risk; deaths are not reported in the registry record. The original sample-size justification, analysis populations, and missing-data methods are also not reported.